Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM.

Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.

PMID:
31075726
2.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
3.

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G.

Cancer Cell. 2019 Feb 11;35(2):204-220.e9. doi: 10.1016/j.ccell.2019.01.006.

PMID:
30753823
4.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG.

J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z.

5.

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M.

Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007.

PMID:
30423297
6.

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.

Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM.

Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.

PMID:
30380460
7.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
8.

Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.

Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X.

Am J Pathol. 2018 Nov;188(11):2487-2496. doi: 10.1016/j.ajpath.2018.07.026. Epub 2018 Sep 8.

PMID:
30201497
9.

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Atkins MB, Tannir NM.

Cancer Treat Rev. 2018 Nov;70:127-137. doi: 10.1016/j.ctrv.2018.07.009. Epub 2018 Jul 20. Review.

10.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

PMID:
29641297
11.

Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.

Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y.

Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.

12.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

13.

Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Tannir NM, Pal SK, Atkins MB.

Oncologist. 2018 May;23(5):540-555. doi: 10.1634/theoncologist.2017-0534. Epub 2018 Feb 27. Review.

14.

A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.

Msaouel P, Tannir NM, Walker CL.

Clin Cancer Res. 2018 May 1;24(9):2044-2049. doi: 10.1158/1078-0432.CCR-17-3296. Epub 2018 Feb 12.

15.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.

PMID:
29377755
16.

Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.

Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ.

J Radiosurg SBRT. 2017;5(1):25-34.

17.

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL.

Neoplasia. 2018 Jan;20(1):32-43. doi: 10.1016/j.neo.2017.11.002. Epub 2017 Nov 27.

18.

Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control.

Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, Tam AL.

J Bone Joint Surg Am. 2017 Nov 15;99(22):1916-1926. doi: 10.2106/JBJS.16.01182.

PMID:
29135665
19.

Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.

Kang HC, Gupta S, Wei W, Lu L, Matrana MR, Tannir NM, Choi H.

AJR Am J Roentgenol. 2017 Dec;209(6):1278-1284. doi: 10.2214/AJR.17.18018. Epub 2017 Oct 24.

20.

Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.

Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X.

Carcinogenesis. 2017 Oct 26;38(11):1129-1135. doi: 10.1093/carcin/bgx083.

21.

A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.

Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E.

J Natl Compr Canc Netw. 2017 Sep;15(9):1111-1120. doi: 10.6004/jnccn.2017.0149.

PMID:
28874596
22.

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30238-0. doi: 10.1016/j.clgc.2017.07.028. [Epub ahead of print]

23.

Editorial Comment.

Shah AY, Tannir NM.

Urology. 2017 Nov;109:132. doi: 10.1016/j.urology.2017.06.049. Epub 2017 Sep 1. No abstract available.

PMID:
28867144
24.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

25.

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma.

Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG.

Sci Rep. 2017 Aug 17;7(1):8540. doi: 10.1038/s41598-017-08363-6.

26.

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E.

Cancer Res. 2017 Oct 1;77(19):5313-5326. doi: 10.1158/0008-5472.CAN-17-0986. Epub 2017 Aug 14.

27.

NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.

Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG.

Cancer Res. 2017 Sep 15;77(18):4835-4845. doi: 10.1158/0008-5472.CAN-17-0143. Epub 2017 Jul 28.

28.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
29.

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B.

Clin Genitourin Cancer. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005. [Epub ahead of print]

PMID:
28711490
30.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

31.

Papillary Renal Cell Carcinoma: A Family Portrait.

Flippot R, Compérat E, Tannir NM, Malouf GG.

Eur Urol. 2018 Jan;73(1):79-80. doi: 10.1016/j.eururo.2017.06.004. Epub 2017 Jun 19. No abstract available.

PMID:
28642022
32.

Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes.

Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1436-1442. doi: 10.1158/1055-9965.EPI-17-0141. Epub 2017 Jun 16.

33.

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.

Malouf GG, Joseph RW, Shah AY, Tannir NM.

Clin Adv Hematol Oncol. 2017 May;15(5):409-418. Review.

PMID:
28591094
34.

Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X.

Cancer. 2017 Sep 15;123(18):3617-3627. doi: 10.1002/cncr.30707. Epub 2017 May 23.

35.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

36.

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Tannir NM, Schwab G, Grünwald V.

Curr Oncol Rep. 2017 Feb;19(2):14. doi: 10.1007/s11912-017-0566-9. Review.

37.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

38.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
39.

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.

Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM.

Oncotarget. 2017 Jun 27;8(26):42149-42158. doi: 10.18632/oncotarget.15011.

40.

Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, Grégoire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Tannir NM, Leroy X.

Histopathology. 2017 Jun;70(7):1089-1097. doi: 10.1111/his.13167. Epub 2017 Mar 21.

PMID:
28106924
41.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

42.

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity.

Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X.

Br J Cancer. 2017 Jan 3;116(1):77-84. doi: 10.1038/bjc.2016.392. Epub 2016 Dec 1.

43.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

44.

Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?

Msaouel P, Malouf GG, Tannir NM.

Eur Urol. 2017 Mar;71(3):415-416. doi: 10.1016/j.eururo.2016.10.034. Epub 2016 Nov 2. No abstract available.

PMID:
27816301
45.

Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.

Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM.

Clin Genitourin Cancer. 2017 Apr;15(2):e205-e208. doi: 10.1016/j.clgc.2016.07.016. Epub 2016 Jul 22.

PMID:
27568124
46.

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.

de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK.

Cancer Immunol Res. 2016 Oct;4(10):820-822. Epub 2016 Aug 18.

47.

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.

J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106.

48.

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P.

J Immunother Cancer. 2016 Jun 21;4:36. doi: 10.1186/s40425-016-0139-8. eCollection 2016.

49.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators.

Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.

PMID:
27279544
50.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM.

Clin Cancer Res. 2016 Dec 15;22(24):6236-6246. Epub 2016 Jun 2.

Supplemental Content

Loading ...
Support Center